You may think that walking during a race leads to slower times. And that’s okay, because it’s an easy misconception to put stock into. Runner’s World contributor Liv Paxton also believed in that ...

Maddie Hale initially began dog walking to get out of the house after studying at home all day as a teenager. School had long been a source of anxiety — she describes having “awful, awful panic ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

The Northwest’s only commercial nuclear power plant, the Columbia Generating Station, was manually shut down early Thursday morning due to a mechanical problem. Energy Northwest workers shut the plant ...

Turiya Advisors exited a stake in CXW during the fourth quarter, selling 479,000 shares. The quarter-end position value decreased by $9.75 million as a result of the exit. The position previously ...

I’m not sure there’s a person in the world who could scroll past a short video of a man calmly letting a 20-foot python slither across a grassy park without stopping. The snake is enormous, thicker ...

Add Yahoo as a preferred source to see more of our stories on Google. Reticulated pythons are the longest snakes in the world, capable of reaching 20 feet or more and weighing well over 200 pounds.

It was a sunny day in Lexington, South Carolina on Jan. 8, 2026, the perfect day for walking. Kristin Greene, who had traveled over three hours from her home in Raleigh-Durham, North Carolina, was ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...